Belapectin, a galectin-3 inhibitor, is being developed for the treatment of Metabolic Dysfunction-Associated SteatoHepatitis or MASH cirrhosis and portal hypertension. In the U.S. cohort of the ...
The trial tested belapectin, a drug designed for the treatment of Metabolic Dysfunction-Associated SteatoHepatitis (MASH) cirrhosis and portal hypertension. With a market capitalization of $88.5 ...
Additional analysis of data from the NAVIGATE trial showed statistically significant 68.1% (p=0.02) reduction in the incidence of new varices with belapectin vs placebo in per-protocol patients ...
The NAVIGATE trial top-line results showed that while the incidence of varices at 18 months was 43.2% lower in patients treated with belapectin 2 mg vs placebo, the composite endpoint did not ...
Galectin's lead drug belapectin is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases ...
The NAVIGATE trial top-line results showed that while the incidence of varices at 18 months was 43.2% lower in patients treated with belapectin 2 mg vs placebo, the composite endpoint did not ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback